{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T13:47:13Z","timestamp":1648561633870},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2004,9,1]],"date-time":"2004-09-01T00:00:00Z","timestamp":1093996800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Science Inc"],"published-print":{"date-parts":[[2004,9]]},"DOI":"10.1007\/s11906-004-0051-3","type":"journal-article","created":{"date-parts":[[2007,5,24]],"date-time":"2007-05-24T15:27:58Z","timestamp":1180020478000},"page":"342-345","source":"Crossref","is-referenced-by-count":4,"title":["The use of selective aldosterone antagonists"],"prefix":"10.1007","volume":"6","author":[{"given":"Myron H.","family":"Weinberger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"51_CR1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709\u2013717. This was the first study to demonstrate the efficacy of a mineralocorticoid receptor blocker in the treatment of congestive heart failure. In addition, this study established the improved survival of such patients, a unique benefit.","journal-title":"N Engl J Med"},{"key":"51_CR2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ: Eplerenone, a selective aldosterone blocker in mild-to-moderate hypertension. Am J Hypertension 2002, 15:709\u2013716. This was the first large study to demonstrate the dose-dependent antihypertensive efficacy of eplerenone in comparison with spironolactone and placebo.","journal-title":"Am J Hypertension"},{"key":"51_CR3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, et al.: Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 2002, 40:117\u2013123.","journal-title":"Hypertension"},{"key":"51_CR4","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","volume":"41","author":"JM Flack","year":"2003","unstructured":"Flack JM, Oparil S, Pratt JH, et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 2003, 41:1148\u20131155.","journal-title":"J Am Coll Cardiol"},{"key":"51_CR5","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St-Hillaire R, et al.: Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003, 41:1021\u20131026. This study demonstrated the efficacy and tolerability of eplerenone in treating systolic hypertension in the elderly patient.","journal-title":"Hypertension"},{"key":"51_CR6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0002-9149(03)00461-2","volume":"92","author":"W White","year":"2003","unstructured":"White W, Carr A, Krause S, et al.: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol 2003, 92:38\u201342.","journal-title":"Am J Cardiol"},{"key":"51_CR7","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","volume":"25","author":"E Burgess","year":"2002","unstructured":"Burgess E, Lacouciere Y, Ruilope L, et al.: Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther 2002, 25:2388\u20132404.","journal-title":"Clin Ther"},{"key":"51_CR8","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","volume":"108","author":"B Pitt","year":"2003","unstructured":"Pitt B, Reichek N, Willenbrock R, et al.: Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 2003, 108:1831\u20131838.","journal-title":"Circulation"},{"key":"51_CR9","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, et al.: Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 2004, 93:990\u2013996.","journal-title":"Am J Cardiol"},{"key":"51_CR10","first-page":"6A","volume":"14","author":"M Epstein","year":"2003","unstructured":"Epstein M, Weinberger MH, Lewin A, et al.: The selective aldosterone blocker, eplerenone, reduces proteinuria without concomitant hyperkalemia (abstract). J Am Soc Nephrol 2003, 14:6A.","journal-title":"J Am Soc Nephrol"},{"key":"51_CR11","doi-asserted-by":"crossref","first-page":"24A","DOI":"10.1016\/S0895-7061(02)02333-6","volume":"15","author":"M Epstein","year":"2002","unstructured":"Epstein M, Buckalew V Jr, Martinez F, et al.: Antiproteinuric efficacy of eplerenone, enalapril and eplerenone\/enalapril combination therapy in diabetic hypertensives with microalbuminuria (abstract). Am J Hypertension 2002, 15:24A.","journal-title":"Am J Hypertension"},{"key":"51_CR12","doi-asserted-by":"crossref","unstructured":"Epstein M, Buckalew V, Altomirano J, et al.: Eplerenone reduces proteinuria in type II diabetes mellitus: implications for aldosterone involvement in the pathogenesis of renal dysfunction. J Am Coll Cardiol 2002, 39:Suppl A.","DOI":"10.1016\/S0735-1097(02)81115-9"},{"key":"51_CR13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","volume":"60","author":"X Jeunemaitre","year":"1987","unstructured":"Jeunemaitre X, Chatellier G, Kreft-Jais C, et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987, 60:820\u2013825.","journal-title":"Am J Cardiol"},{"key":"51_CR14","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archinte.163.13.1543","volume":"163","author":"NK Hollenberg","year":"2003","unstructured":"Hollenberg NK, Williams GH, Anderson R, et al.: Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med 2003, 163:1543\u20131548. This study demonstrated the increased tolerability as well as equivalent antihypertensive efficacy of eplerenone in comparison with amlodipine in isolated systolic hypertension.","journal-title":"Arch Intern Med"},{"key":"51_CR15","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1161\/hc4201.097944","volume":"104","author":"P Verdecchia","year":"2001","unstructured":"Verdecchia P, Porcellati C, Reboldi G, et al.: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001, 104:2039\u20132066.","journal-title":"Circulation"},{"key":"51_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41\u201346.","journal-title":"Am J Med"},{"key":"51_CR17","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.HYP.0000124251.06056.8e","volume":"43","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Benjamin EJ, et al.: Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. Hypertension 2004, 43:957\u2013962.","journal-title":"Hypertension"},{"key":"51_CR18","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309\u20131321. This study demonstrated the efficacy and improved survival of patients with congestive heart failure treated with eplerenone.","journal-title":"N Engl J Med"},{"key":"51_CR19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.RES.67.6.1355","volume":"67","author":"CG Brilla","year":"1990","unstructured":"Brilla CG, Pick R, Tan LB, et al.: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990, 67:1355\u20131364.","journal-title":"Circ Res"},{"key":"51_CR20","first-page":"E883","volume":"271","author":"MJ Young","year":"1996","unstructured":"Young MJ, Funder JW: The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 1996, 271:E883-E888.","journal-title":"Am J Physiol"},{"key":"51_CR21","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","volume":"141","author":"R Rocha","year":"2000","unstructured":"Rocha R, Stier CT Jr, Kifor I, et al.: Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinol 2000, 141:3871\u20133878.","journal-title":"Endocrinol"},{"key":"51_CR22","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, et al.: Aldsoterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kid Int 2003, 63:1791\u20131800.","journal-title":"Kid Int"},{"key":"51_CR23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1161\/01.HYP.0000123572.45556.a5","volume":"43","author":"H Oberleithner","year":"2004","unstructured":"Oberleithner H, Ludwig T, Riethmuller C, et al.: Human endothelium: target for aldosterone. Hypertension 2004, 43:952\u2013956.","journal-title":"Hypertension"},{"key":"51_CR24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0008-6363(03)00333-X","volume":"58","author":"A Schafer","year":"2003","unstructured":"Schafer A, Fraccarollo D, Hidemann SK, et al.: Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res 2003, 58:655\u2013662.","journal-title":"Cardiovasc Res"},{"key":"51_CR25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1055\/s-0037-1613404","volume":"89","author":"A Schafer","year":"2003","unstructured":"Schafer A, Fraccarollo D, Hildemann S, et al.: Inhibition of platelet aggregation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003, 89:1024\u20131030.","journal-title":"Thromb Haemost"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0051-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-004-0051-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-004-0051-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:16:09Z","timestamp":1559420169000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-004-0051-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,9]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["51"],"URL":"https:\/\/doi.org\/10.1007\/s11906-004-0051-3","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,9]]}}}